Hematological parameters during concurrent chemoradiotherapy as potential prognosticators in patients with stage IIB cervical cancer
| Autor: | Hee-Sug Ryu, Mison Chun, Eun Ju Lee, Young-Taek Oh, O Kyu Noh, Oyeon Cho, Suk-Joon Chang |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty medicine.medical_treatment Lymphocyte Uterine Cervical Neoplasms Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine RC254-282 Aged Neoplasm Staging Cervical cancer business.industry Hazard ratio Neoplasms. Tumors. Oncology. Including cancer and carcinogens Cancer Stage IIB Cervical Cancer Chemoradiotherapy General Medicine Middle Aged Prognosis medicine.disease Radiation therapy 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Multivariate Analysis Absolute neutrophil count Female Cisplatin business |
| Zdroj: | Tumor Biology, Vol 39 (2017) |
| ISSN: | 1423-0380 1010-4283 |
| Popis: | We hypothesized that hemoglobin levels, absolute neutrophil count, and absolute lymphocyte count were associated with radiotherapy response and cancer progression and that they might reflect tumor repopulation during concurrent chemoradiotherapy. This study aimed to investigate these hematological parameters as prognosticators of cervical cancer. We analyzed 105 stage IIB cervical cancer patients treated with concurrent chemoradiotherapy, using log-rank tests and multivariate analyses. Hazard ratios were calculated weekly to evaluate changes in hemoglobin, absolute neutrophil count, and absolute lymphocyte count that were associated with disease-specific survival. Patients were categorized into the high hematological risk (patients with low hemoglobin plus high absolute neutrophil count and/or low absolute lymphocyte count) and the low hematological risk (others) groups according to the median cutoff values. During the second week of concurrent chemoradiotherapy, hematological factors were significantly associated with survival. In multivariate analysis, hematological risk was independently associated with disease-specific survival and progression-free survival. The 5-year disease-specific survival and progression-free survival rates in the high hematological risk group were significantly lower compared with those in the low hematological risk group (81.6% vs 92.6%, p = 0.0297; 73.7% vs 89.3%, p = 0.0163, respectively). During the second week of concurrent chemoradiotherapy, the hematological parameters could predict treatment outcome in stage IIB cervical cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|